Skyrizi access in Saudi Arabia: the SFDA Personal Importation Program
How KSA patients legally obtain Skyrizi (risankizumab-rzaa) when the locally registered indication, payer coverage, or stocked presentation does not match what the prescribing specialist has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Skyrizi (risankizumab-rzaa) is an interleukin-23 p19 subunit inhibitor manufactured by AbbVie, approved by the US FDA across four indications: moderate to severe plaque psoriasis (2019), active psoriatic arthritis (2022), moderately to severely active Crohn's disease (2022), and moderately to severely active ulcerative colitis (June 2024). With the 2024 UC approval Skyrizi became the first IL-23 specific inhibitor approved across both Crohn's and UC. The Saudi Food and Drug Authority (SFDA) has registered Skyrizi through AbbVie's regional affiliate for at least the psoriasis indication, with indication breadth at the local agent level lagging the FDA timeline, particularly for the 2024 UC indication. KSA patients use the SFDA Personal Importation Program to access Skyrizi when the local indication is too narrow, the IBD induction presentation is not stocked, or Bupa Arabia, Tawuniya, or MedGulf has declined biologic coverage for the patient's specific indication. Reserve Meds coordinates US-side sourcing, cold-chain logistics, and the documentation packet your gastroenterologist, rheumatologist, or dermatologist needs.
Reserved for you.
Why KSA patients need Skyrizi through the named-patient pathway
The Kingdom of Saudi Arabia operates one of the most mature pharmaceutical regulatory frameworks in the Gulf Cooperation Council, and Saudi Vision 2030's Health Sector Transformation Program is expanding tertiary gastroenterology, rheumatology, and dermatology capacity through the Centers of Excellence model. AbbVie has prioritized Skyrizi as a post-Humira growth asset, and the drug is on the SFDA register. The gap is rarely "Skyrizi does not exist in KSA." The gap is which indication is registered locally, which indication the patient actually has, and what the payer will fund.
Specific patterns surface in the Saudi market. A patient with moderately to severely active ulcerative colitis whose gastroenterologist has documented the clinical case for IL-23p19 selective blockade, where the local market has Skyrizi listed for plaque psoriasis but UC reimbursement has not yet caught up to the June 2024 FDA approval. A patient with active psoriatic arthritis whose rheumatologist has stepped through methotrexate, anti-TNF, and ustekinumab, where Bupa Arabia or Tawuniya has approved Skyrizi for plaque psoriasis only and not the PsA indication. A patient with Crohn's disease whose specialist has named Skyrizi specifically (versus Stelara or anti-TNF) and the hospital pharmacy does not stock the 600 mg IV induction vial needed to start therapy. A patient who has failed prior anti-TNF or anti-IL-12/23 (ustekinumab) where the specialist has documented IL-23p19 selectivity as the next-line option.
In each pattern, the patient is not seeking off-label use. The patient is seeking an FDA-approved and globally registered indication that the local KSA market either has not caught up to or does not fund. The SFDA PIP is the lawful mechanism.
The SFDA Personal Importation Program for Skyrizi
The Personal Importation Program allows an SCFHS-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognized reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable for the patient. The framework explicitly contemplates immunology, gastroenterology, rheumatology, and dermatology therapies. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector via the Ghad digital regulatory platform.
A complete application includes a clinical justification letter from the treating physician (diagnosis with ICD-10 coding, severity scoring, prior therapies attempted with documented outcomes, why a locally registered alternative is unsuitable, and the specific drug, dose, and duration requested), SCFHS registration verification in dermatology, rheumatology, or gastroenterology, an anonymized patient identifier linked to the hospital record, full product details (brand name, generic name, manufacturer, country of origin, strength, dosage form, pack size, requested quantity, lot, and expiry), the destination dispensing facility license, and a chain-of-custody plan from the US release point through international transit with cold-chain validation to the receiving Saudi pharmacy.
For Skyrizi specifically, two elements drive the clinical-justification angle. First, tuberculosis screening before initiation is mandatory per the FDA label, with treatment of latent TB before starting therapy. The clinical justification letter documents the screening result (interferon-gamma release assay or tuberculin skin test) and any treatment for latent TB completed before therapy. This is a meaningful difference from Dupixent, which has no TB requirement. Second, the IL-23p19 selectivity argument differentiates Skyrizi from ustekinumab (Stelara), which targets the shared p40 subunit of IL-12 and IL-23. For a patient who has failed Stelara, the prescriber documents the selective mechanism and clinical rationale for switching. For an IBD case, the prescriber specifies the IV induction phase (600 mg at week 0, 4, 8 for Crohn's; 1200 mg at week 0, 4, 8 for UC) and the SC maintenance phase (360 mg every 8 weeks for Crohn's; 180 mg or 360 mg every 8 weeks for UC), noting that the UC induction is unique and not interchangeable with the Crohn's dose.
Approval timelines for routine cases (recognized reference-authority drug, well-documented indication, established institution) typically run 10 to 21 business days. Complex cases, including first-time IBD induction filings, can extend to 6 to 10 weeks.
Where Skyrizi gets dispensed in Saudi Arabia
For SC maintenance dosing, any major tertiary or private center with 2 to 8 degrees Celsius cold-chain storage and continuous monitoring qualifies. For IV induction in Crohn's and ulcerative colitis, the dispensing facility additionally needs an infusion suite with pharmacy reconstitution capability. The institutions that handle both modalities as established workflow include King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah; King Abdulaziz Medical City (KAMC) and the Ministry of National Guard Health Affairs network (MNGHA); King Saud University Medical City (KSUMC); Dr. Sulaiman Al Habib Medical Group (HMG); Saudi German Health hospitals; Dr. Soliman Fakeeh Hospital in Jeddah; and Dallah Hospital in Riyadh. These centers have established gastroenterology, rheumatology, and dermatology programs with experienced PIP filers in the import pharmacy.
For physicians at smaller hospitals, the practical pattern is to route the case through an SFDA-licensed specialty importer in Riyadh or Jeddah. The importer files the PIP application, the drug moves to a partner infusion center for IBD induction, and SC maintenance dispensing proceeds through the institutional pharmacy thereafter.
Real cost picture for Skyrizi in Saudi Arabia
US WAC for Skyrizi is approximately USD 23,838 per single dose as of early 2026, with AbbVie disclosing list-price updates on an annual cadence. For the plaque psoriasis maintenance regimen (150 mg every 12 weeks after induction), annual gross cost at WAC runs in the USD 90,000 to USD 100,000+ range per patient-year. For Crohn's disease and ulcerative colitis the IV induction phase (600 mg or 1200 mg at weeks 0, 4, 8) plus SC maintenance produces a first-year gross cost that is materially higher than the psoriasis steady state.
At the SAR peg of approximately 3.75 to the dollar, annual psoriasis maintenance translates to roughly SAR 338,000 to SAR 375,000 at US WAC equivalents, with first-year IBD cost meaningfully above that during the induction phase. International logistics for a cold-chain biologic shipment to Riyadh or Jeddah typically runs USD 800 to USD 2,500 (approximately SAR 3,000 to SAR 9,400), with the IV induction vial often shipped separately from SC maintenance doses to align with the dispensing schedule. SFDA permit fees and customs handling are nominal relative to drug cost.
On the payer side, Bupa Arabia, Tawuniya, MedGulf Arabia, and other CCHI-regulated insurers handle biologic claims case by case. The Skyrizi Complete Savings Card, myAbbVie Assist patient assistance program, and US specialty pharmacy distribution agreements do not extend internationally. Cash-pay is the default operating posture.
Typical timeline for Skyrizi in Saudi Arabia
SFDA routine processing is typically 10 to 21 business days from a complete filing. Cold-chain shipment adds 2 to 3 days versus ambient because validated thermal packaging and continuous temperature logging are mandatory; AbbVie's labeling allows a single limited excursion to room temperature before administration, after which the dose must be used or discarded. End-to-end, most plaque psoriasis or PsA cases complete within 4 to 7 weeks from first complete documentation. IBD induction cases run longer because the infusion center scheduling, the IV vial dispense, and the subsequent SC maintenance schedule must be coordinated as a series, often extending the practical first-cycle window to 6 to 10 weeks.
What your physician needs to provide
For an SCFHS-licensed dermatologist, rheumatologist, or gastroenterologist prescribing Skyrizi through the PIP pathway, the clinical justification letter is the cornerstone of the application. The letter documents diagnosis with ICD-10 coding (plaque psoriasis with PASI or BSA score, psoriatic arthritis with joint count and CASPAR criteria, Crohn's disease with endoscopic or imaging confirmation and CDAI or HBI score, or ulcerative colitis with endoscopic confirmation and Mayo score), prior therapy history with documented outcomes (topical or systemic therapy, conventional DMARDs, anti-TNF agents, ustekinumab where relevant), and the clinical rationale for IL-23p19 selectivity.
The letter specifies the exact dosing plan per the FDA-approved label. Plaque psoriasis and PsA: 150 mg SC at week 0, week 4, then every 12 weeks. Crohn's disease: 600 mg IV at week 0, 4, 8, then 360 mg SC at week 12 and every 8 weeks. Ulcerative colitis: 1200 mg IV at week 0, 4, 8, then 180 mg or 360 mg SC at week 12 and every 8 weeks. The monitoring plan documents baseline TB screening (interferon-gamma release assay or tuberculin skin test) with treatment of latent TB before therapy initiation, hepatitis B screening, baseline CBC, and ongoing clinical assessment for serious infection.
The treating physician's SCFHS registration, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. The physician also commits, with the dispensing pharmacy, to reporting any adverse event through the SFDA National Pharmacovigilance Center for the full course of therapy.
Common questions about Skyrizi in Saudi Arabia
Will Bupa Arabia, Tawuniya, or MedGulf cover Skyrizi for my UC or PsA indication? Each plan handles biologic claims case by case. Many KSA plans cover Skyrizi for plaque psoriasis on formulary but require separate prior authorization for PsA, Crohn's, or UC. Pre-authorization with the clinical justification letter attached is the typical route. We supply the documentation that allows the insurer to assess; the claim itself sits with you or your hospital.
Why TB screening before Skyrizi? The FDA label requires screening for latent and active tuberculosis before initiation, with treatment of latent TB completed before starting therapy. This applies to all IL-23 and IL-12/23 inhibitors and anti-TNF agents. Dupixent does not carry this requirement; Stelara does. Your specialist orders the IGRA or TST as part of the workup.
Skyrizi versus Stelara, which is right for my Crohn's or UC? Both target the IL-23 axis, but Skyrizi binds the p19 subunit of IL-23 specifically while Stelara binds the shared p40 subunit of IL-12 and IL-23. For a patient who has failed Stelara, IL-23p19 selectivity is often the prescriber's rationale for switching. The choice rests with your gastroenterologist or dermatologist, not with Reserve Meds.
My physician is at HMG Riyadh. Can they sign the PIP? Yes. SCFHS-licensed specialists at HMG, KFSH&RC, KAMC, MNGHA, KSUMC, Saudi German, Fakeeh, and Dallah all have signing authority on PIP applications under their institutional license.
How does the IV induction work for IBD? Skyrizi's induction for Crohn's disease and ulcerative colitis is administered as a 600 mg or 1200 mg IV infusion at weeks 0, 4, and 8 in a clinical infusion suite. After week 12 the patient transitions to SC maintenance, typically delivered via on-body injector. Coordination with the destination infusion center is part of our case-management workflow before the first IV dose ships.
What about live vaccines? Live vaccines should be avoided during Skyrizi treatment. Your physician will sequence any necessary live vaccinations before therapy initiation as part of the pre-treatment workup.
Where Reserve Meds fits in Skyrizi cases
Reserve Meds is a US-based concierge coordinator. We do not replace your gastroenterologist, rheumatologist, or dermatologist, we do not replace SFDA, and we do not replace your dispensing pharmacy. For Skyrizi specifically, we orchestrate US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits to the SFDA Personal Importation Program, coordinate validated cold-chain logistics with continuous temperature logging into Riyadh or Jeddah, and assign a single named coordinator through induction and maintenance phases. For IBD induction cases we additionally coordinate with the destination infusion center on scheduling before the IV vial ships. No prior Reserve Meds case experience for Skyrizi is logged yet; standard NPP coordination under our cold-chain biologic playbook applies.
Next step
If your Saudi specialist has prescribed Skyrizi and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.